Shanghai HeartCare Medical Technology Corporation Limited (“HeartCare”) has approved a new equity incentive package, granting 560,000 H-share awards to 13 employees on 14 September 2026 under its 2025 H Share Incentive Scheme.

The grant represents approximately 1.83% of HeartCare’s outstanding H shares and 1.44% of the company’s total issued share capital (both figures exclude treasury shares). The awards are issued at nil consideration, compared with the 14 September closing price of HK$49.78 per H share.

Structure and Vesting • Composition: 56,000 one-year awards and 504,000 three-year awards. • Schedule: Vesting spans four assessment years (2026–2029). Awards for 2026–2027 vest on 30 September of the following year. Awards for 2028–2029 vest in two tranches—30 September of the following year and 31 March of the year after. Vesting may be extended to 31 March 2031 if performance targets are unmet.

Performance Conditions Individual grantees must achieve a minimum “B” rating in annual evaluations. Group financial targets require year-on-year revenue increases of 47% (2026), 40% (2027), 35% (2028) and 35% (2029). Operational or market-capitalisation metrics set by the board will also apply.

Clawback Provisions The board retains the right to cancel or recover vested or unvested awards in cases of fraud, serious misconduct, reputational harm, or material financial misstatements.

Scheme Capacity Following the current issuance, 2.90 million H shares remain available for future awards, equal to 9.47% of outstanding H shares and 7.45% of total issued share capital.

Regulatory Context No grantee is a director, chief executive, substantial shareholder or related-entity participant, and no individual grant exceeds the 1% cap stipulated by Hong Kong Listing Rule 17.03D(1). Consequently, shareholder approval is not required for this grant. The company has provided no financial assistance for award acquisition.

The announcement was authorised by Chairman Wang Guohui and released in Shanghai on 14 September 2026.